Mr. Becker has more than 15-years of experience as a drug developer, entrepreneur, company executive, Wall Street securities analyst and financial advisor.

Before establishing MD Becker Partners LLC (http://www.mdbpartners.com) in 2008, he was president and chief executive officer of several publicly-traded biotechnology companies including commercial-stage Cytogen Corporation and development-stage VioQuest Pharmaceuticals, Inc.

While at Cytogen, Mr. Becker held positions of increasing responsibility, including Vice President of Business Development, Industry Relations, Investor Relations and Chief Executive Officer of AxCell Biosciences, a subsidiary of Cytogen focused on signal transduction pathways. During his tenure at Cytogen, Mr. Becker raised in excess of $130 million in new capital through both public offerings and private placements and in-licensed Caphosol©, a novel treatment for oral mucositis and xerostomia.

Prior to joining Cytogen, Mr. Becker was with Wayne Hummer Investments LLC, a Chicago-based regional brokerage firm, where he held senior positions as a biotechnology securities analyst, financial advisor and portfolio manager. He was also the founder and Executive Editor of Beck on Biotech, a monthly biotechnology investment newsletter published from July 1998 through March 2001.

Mr. Becker is past Chairman and member of the board of trustees with BioNJ, which was founded in 1994 by New Jersey biotechnology industry CEOs to serve as the voice of and advocate for the biotechnology industry in New Jersey. He is a member of the National Investor Relations Institute (NIRI), New Jersey Technology Council (NJTC) and the Pharmaceutical Consulting Consortium, Inc. (PCCI). Mr. Becker placed as a finalist for the Ernst & Young Entrepreneur of the Year award in both 2004 and 2005 and was listed in BusinessWeek's "CEO's 40 and Under" article in December 2006. He attended DePaul University in Chicago, Illinois.

MD Becker Partners newsletter site can be found at: http://blog.mdbpartners.com